Ground flour pharmaceuticals lecture 2 bus model canvas
•Download as PPT, PDF•
0 likes•9,152 views
The document discusses developing new radiotracers for positron emission tomography (PET) imaging using green fluorescent protein (GFP) technology. This allows for fast, multi-platform synthesis of short-lived radiotracers for indications like pediatric neuroblastoma and Parkinson's disease. Initial targets are developing the methodology, understanding regulatory processes, and conducting animal and clinical studies. The business model involves selling radiotracers and precursors to radiopharmacies, hospitals, and imaging centers.
Report
Share
Report
Share
![I-Corps 10/11/11 ,[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Cybele final presentation
Cybele is developing a Huntington's disease cell model using induced pluripotent stem cells to enable drug discovery. The team aims to create affected medium spiny neurons in vitro that can be used by academic researchers and pharmaceutical companies to identify potential drug targets and test compounds. Cybele is exploring commercializing purified cell populations for research or providing screening services using their cell model with partners. The company's goal is to accelerate Huntington's disease drug development and reduce costs by enabling earlier testing and failure of non-viable compounds.
Epigen Biosciences I-Corps@NIH 121014
This document summarizes the progress and findings of Team 12 in developing a drug to treat or prevent chemotherapy-induced peripheral neuropathy (CIPN). Through interviews with 104 people, including physicians, academics, and pharmaceutical companies, the team validated that CIPN is a significant problem with no fully effective treatments. Experts said prophylaxis would be valuable and phase 1 efficacy is possible. The team identified the need for preclinical data on nerve function and relevant cancer types. Pharmaceutical companies indicated interest in preclinical assets for $10M and phase 1 programs for $50-100M. The team plans to submit a grant for preclinical/safety studies and future clinical trials to generate the necessary data.
Sol padis dec10-llp-2013
The document summarizes interactions and meetings related to developing treatments for Chagas disease. It notes 75 total interactions in pharma, Chagas KOLs, veterinary, and diagnostics. Key mentors and advisors are listed. The remainder of the document outlines progress in defining the problem and opportunity, building an ecosystem of partners, evaluating product and market options, developing a business model and strategy, and achieving investor readiness.
Result care lean launchpad week 1 slides v2
This document outlines the development of a startup called ResultCare that aims to provide physicians with real-time evidence, guidelines, and expert opinions to help guide diagnostic and treatment decisions. The founders conducted over 100 customer interviews with physicians, laboratories, payers, and other partners to define their customer segments, value propositions, key activities, and partners. They discovered the greatest needs were among specialty laboratories seeking to gain payer coverage and physician users needing diagnostic testing guidance. The founders have raised an initial $75k and are working on the beta release of their evidence and cost guidance engine to begin acquiring users and contracting with specialty laboratories.
Nesher Tech I-Corps@NIH 121014
This document summarizes the business model development process of Nesher Technologies Inc., which is developing a single molecule detection technology. Through interviews with over 90 academic researchers, Nesher learned that researchers are interested in software to analyze single molecule data rather than capital equipment. Nesher also explored partnering with microscope and biotech companies but did not find product-market fit. Nesher pivoted to a software-focused business model, developing single molecule analysis software to sell to academic researchers.
Affinity I-Corps@NIH 121014
Affinity Therapeutics is developing drug-coated vascular grafts and drug-eluting wraps to reduce stenosis rates and failure in hemodialysis patients. They interviewed 128 potential customers including nephrologists, surgeons, and patients, and identified two minimum viable products - a coated graft and a drug-eluting wrap that could be used with fistulas or grafts. Based on further interviews and analysis, they determined the wrap has potential for a larger market. Affinity plans to submit a Phase II SBIR grant to further develop the wrap MVP and continue cultivating relationships with key opinion leaders and medical centers.
CardiaX I-Corps@NIH 121014
The team conducted over 100 interviews to validate treating atrial fibrillation using vagus nerve stimulation. Early interviews focused on advanced AF patients but later showed a need to treat early-stage AF patients. The team received funding to develop the approach and acquired a CE marked implantable pulse generator. They completed a feasibility study and are seeking funds for a larger trial to further prove clinical outcomes.
Tomo Wavelabs I-Corps@NIH 121014
The document discusses a new technology for guiding cryoablation of prostate cancer using optoacoustic tomography (OAT) to provide high resolution temperature monitoring and visualization of the ice ball, aiming to reduce rectal damage, impotence, and cancer recurrence. It provides estimates of the total available market, served available market, and target market for the technology, projecting sales of 600 units for $84 million. Customer interviews conducted during an I-Corps program helped shift the business model from direct sales to physicians to partnerships with cryoablation providers.
Recommended
Cybele final presentation
Cybele is developing a Huntington's disease cell model using induced pluripotent stem cells to enable drug discovery. The team aims to create affected medium spiny neurons in vitro that can be used by academic researchers and pharmaceutical companies to identify potential drug targets and test compounds. Cybele is exploring commercializing purified cell populations for research or providing screening services using their cell model with partners. The company's goal is to accelerate Huntington's disease drug development and reduce costs by enabling earlier testing and failure of non-viable compounds.
Epigen Biosciences I-Corps@NIH 121014
This document summarizes the progress and findings of Team 12 in developing a drug to treat or prevent chemotherapy-induced peripheral neuropathy (CIPN). Through interviews with 104 people, including physicians, academics, and pharmaceutical companies, the team validated that CIPN is a significant problem with no fully effective treatments. Experts said prophylaxis would be valuable and phase 1 efficacy is possible. The team identified the need for preclinical data on nerve function and relevant cancer types. Pharmaceutical companies indicated interest in preclinical assets for $10M and phase 1 programs for $50-100M. The team plans to submit a grant for preclinical/safety studies and future clinical trials to generate the necessary data.
Sol padis dec10-llp-2013
The document summarizes interactions and meetings related to developing treatments for Chagas disease. It notes 75 total interactions in pharma, Chagas KOLs, veterinary, and diagnostics. Key mentors and advisors are listed. The remainder of the document outlines progress in defining the problem and opportunity, building an ecosystem of partners, evaluating product and market options, developing a business model and strategy, and achieving investor readiness.
Result care lean launchpad week 1 slides v2
This document outlines the development of a startup called ResultCare that aims to provide physicians with real-time evidence, guidelines, and expert opinions to help guide diagnostic and treatment decisions. The founders conducted over 100 customer interviews with physicians, laboratories, payers, and other partners to define their customer segments, value propositions, key activities, and partners. They discovered the greatest needs were among specialty laboratories seeking to gain payer coverage and physician users needing diagnostic testing guidance. The founders have raised an initial $75k and are working on the beta release of their evidence and cost guidance engine to begin acquiring users and contracting with specialty laboratories.
Nesher Tech I-Corps@NIH 121014
This document summarizes the business model development process of Nesher Technologies Inc., which is developing a single molecule detection technology. Through interviews with over 90 academic researchers, Nesher learned that researchers are interested in software to analyze single molecule data rather than capital equipment. Nesher also explored partnering with microscope and biotech companies but did not find product-market fit. Nesher pivoted to a software-focused business model, developing single molecule analysis software to sell to academic researchers.
Affinity I-Corps@NIH 121014
Affinity Therapeutics is developing drug-coated vascular grafts and drug-eluting wraps to reduce stenosis rates and failure in hemodialysis patients. They interviewed 128 potential customers including nephrologists, surgeons, and patients, and identified two minimum viable products - a coated graft and a drug-eluting wrap that could be used with fistulas or grafts. Based on further interviews and analysis, they determined the wrap has potential for a larger market. Affinity plans to submit a Phase II SBIR grant to further develop the wrap MVP and continue cultivating relationships with key opinion leaders and medical centers.
CardiaX I-Corps@NIH 121014
The team conducted over 100 interviews to validate treating atrial fibrillation using vagus nerve stimulation. Early interviews focused on advanced AF patients but later showed a need to treat early-stage AF patients. The team received funding to develop the approach and acquired a CE marked implantable pulse generator. They completed a feasibility study and are seeking funds for a larger trial to further prove clinical outcomes.
Tomo Wavelabs I-Corps@NIH 121014
The document discusses a new technology for guiding cryoablation of prostate cancer using optoacoustic tomography (OAT) to provide high resolution temperature monitoring and visualization of the ice ball, aiming to reduce rectal damage, impotence, and cancer recurrence. It provides estimates of the total available market, served available market, and target market for the technology, projecting sales of 600 units for $84 million. Customer interviews conducted during an I-Corps program helped shift the business model from direct sales to physicians to partnerships with cryoablation providers.
Novoron I-Corps@NIH 121014
The document describes the evolution of a biotech startup's efforts to develop a new drug to treat spinal cord injury (SCI). Initially, the team was optimistic about validating the need and market potential. However, through customer interviews, they learned big pharma is not interested in early-stage SCI drugs due to previous failures. The team then developed a new 36-month plan to generate more rigorous preclinical data for FDA approval and attract partners. They also identified new financing options and pivoted to explore opportunities in multiple sclerosis based on stronger customer interest.
BioHybrid Graft I-Corps@NIH 121014
The document summarizes the progress of Team 21's bio-hybrid vascular graft project. It describes initial market research identifying unmet needs for small diameter vascular grafts. Through customer interviews, the team refined their target markets from coronary artery disease grafts to prioritizing peripheral artery disease grafts. Key lessons included identifying referring physicians as important influencers and pursuing CE mark in the EU followed by FDA approval. The team ended their canvas update at a higher level of investment readiness and prepared to apply for further STTR funding.
Magnamosis inc final presentation 12 10
The document outlines the progress of a team developing a magnetic compression device for surgical anastomoses. It includes:
1) The team has developed a device called Magnamosis to create magnetic compression anastomoses and has achieved milestones including animal trials and FDA approval for human trials.
2) Interviews with surgeons found reducing anastomotic leaks to be a key value proposition, as leaks increase costs and morbidity.
3) The team refined their business model based on feedback, deciding to focus early adoption in academic centers and use value-based pricing between $1,200-250 per device.
Abreos biosciences I-Corps@ NIH 121014
This document appears to be notes from a biotech startup working on drug authentication. It outlines the founders and advisors, progress made in validating customers and markets overseas, developing minimum viable products for different use cases, forming new partnerships, and progress towards an investment ready prototype. The startup has received several grants and is working to develop their prototype and secure further funding.
Liquilume NSF Final Presentation
LiquiLume Diagnostics develops molecular diagnostic devices that can detect individual molecules rapidly and inexpensively. Their initial focus is on nucleic acid testing (NAT) and protein biomarkers. They plan to first sell to research laboratories for research use only, then pursue FDA clearance to sell to clinical labs and hospitals. Their technology allows highly automated sample processing and analysis at low concentrations and low cost compared to standard methods.
Asclepix I-Corps@NIH 121014
The document summarizes the findings from 102 customer interviews conducted by an I-Corps team exploring a novel cancer therapy. Based on the interviews, the team pivoted from targeting head and neck cancer to glioblastoma, identified their customers as pharmaceutical licensing scouts and biotech executives rather than patients or doctors, and adjusted their preclinical strategy and partnerships to focus on demonstrating safety and efficacy while mitigating risks related to their nanotechnology approach.
Data Mining and Big Data Analytics in Pharma
The document proposes software solutions for drug research, including text mining, data warehousing, data mining, database development, and big data analytics. It discusses common challenges in drug research like the high costs and low success rates. It then describes various solutions like text mining patents and research to help identify new research opportunities and reduce duplication of efforts. It provides examples of how various pharmaceutical companies use data mining and warehousing techniques. Overall, the document pitches different IT solutions that can help pharmaceutical and life sciences companies address their research challenges and make their processes more efficient.
GJRS resume Jan 15
This document provides a summary of Greg J Spooner's career and qualifications. It includes his contact information, education history, and over 15 years of professional experience in developing lasers, optics, and medical devices. He has worked at several medical device companies and has 16 issued patents. His focus and expertise are in developing photonics-based medical devices, performing clinical applications research, product development, and regulatory submissions.
Gluco Sentient Final NSF I-Corps presentation
This document proposes a diagnostic platform that leverages existing personal glucose meters to provide direct readouts of target concentrations in patient samples. It suggests using this platform for therapeutic drug monitoring in clinical trials, medical diagnoses, and environmental detection. The initial target market was seen as diabetes patients who already own glucose meters and need HbA1c monitoring. However, immediate drug monitoring during clinical trials was identified as a better market that meets the value propositions of immediacy, low cost, multiple tests, and short development cycles. Partnerships with pharmaceutical companies are proposed, with GlucoSentient providing added value to meter manufacturers and the pharmaceutical companies being key customers and providing financial support.
BIO 2010 Partnering with Patients
The document discusses various ways that nonprofit organizations partner with patients and the medical research community to advance research and drug development. It provides examples of how organizations fund research, develop tools and resources, facilitate clinical trials, advocate for policy changes, and build communities to accelerate the development of new treatments. Specific organizations highlighted include the Alzheimer's Drug Discovery Foundation, Juvenile Diabetes Research Foundation, Multiple Myeloma Research Foundation, ALS Therapy Development Institute, and Genetic Alliance.
2012 DIA EMRs for clinical research
EMR functionality for clinical research has long been dreamed about, but how close to reality is it actually? This presentation lays out some basic facts about the viability (or lack thereof) of using EMRs for Phase 1-3 clinical trials.
D2M Final Presentation Submission for LinkedIn
This feasibility analysis examines developing a nucleic acid detection probe for fungal infections. It discusses the unmet need for rapid and accurate diagnosis of fungal sepsis in immunocompromised patients. Currently, diagnosis can take 2-4 days via blood culture and has low sensitivity. The proposed invention is a DNA-based probe that can detect fungal infections in 4-10 hours with higher sensitivity. The analysis covers the intellectual property landscape, potential licensees in biotech and diagnostics, licensing terms, and financial projections. It estimates the US market size as $900 million annually and projects revenues of $198 million within 5 years of licensing. However, the single patent expires in 2017. The recommendation is to donate the intellectual property to research
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...Medicines Discovery Catapult
The document discusses exploiting medicinal chemistry knowledge to accelerate drug discovery projects through in silico drug design techniques. It provides an agenda for a presentation covering problem statements around long development times, sources for design ideas like literature and patents, techniques for 2D and 3D molecular design including QSAR and docking models, and examples of applying these methods to specific drug targets. The presentation aims to explain how to analyze data rigorously and refine compound designs to find drug candidates faster.Webinar - State of the Discovery Nation 2019
The document is a report on the state of the UK drug discovery industry in 2019. It finds that most small and medium enterprises in the industry are service and supply companies, employing fewer than 20 people. The majority of drug development assets held by UK companies are focused on cancer, anti-infectives, and central nervous system disorders. Artificial intelligence and cell and gene therapies are seen as promising but in need of further validation and data. The report recommends that the government increase funding support and that the Medicines Discovery Catapult continue connecting companies, providing access to datasets and technologies, and helping to validate new models like complex cell models.
Maples PB Resume 010417
This document provides a biography for Phillip B. Maples, Ph.D., the Executive Director of Laurus Bio, LLC. It outlines his over 30 years of experience in cell and gene therapy development, including designing and building over 10 GMP manufacturing facilities. It also lists his roles and accomplishments at various biotech companies, including developing cell and gene therapies for cancer and inherited diseases and leading clinical trials.
Pharma data analytics
Presentation Alliance of European Life Sciences Law Firms
(Julian Hitchcock and Sofie van der Meulen) on legal aspects of big data in pharma. Topics: privacy, IP, medical devices and IVD.
J & J Solutions Executive Summary 1 Page
J & J Solutions has developed a closed system transfer device for safer handling of chemotherapy drugs. Their device eliminates risks of contamination, standardizes compounding to reduce errors, improves workflow efficiency, and reduces costs. They are seeking funding to complete product development including alpha and beta testing, obtain FDA approval, and launch the product to address a $1 billion market that is growing due to increasing cancer rates.
Team1 evening business-strategy_milestone1
23andMe is a privately-held personal genomics company based in Mountain View, CA that was founded in 2007. It provides genetic reports on over 100 diseases, conditions, and traits by analyzing customers' DNA samples. 23andMe aims to be the world's trusted source of personal genetic information while protecting customers' privacy and helping them understand their genetic data. It offers health, ancestry, and community services but lacks focus and customers are often confused by the breadth of information. The company needs to improve its marketing, user interface, and partnerships to help customers act on their genetic insights.
The Case Of Incyte Genomics
1) Incyte Genomics pursued an ambitious business model and patent strategy in the late 1990s and early 2000s that involved sequencing the human genome, patenting gene sequences, and selling subscriptions to genomic databases and licensing the patents.
2) A key part of the strategy was filing over 2,000 patent applications covering about 11,000 human gene sequences to generate licensing revenues, but this strategy faced challenges from the US Patent Office's utility requirement.
3) In 2004, Incyte abandoned its original business model and patent strategy after the US Patent Office rejected many of its patent applications for lack of demonstrating utility and specific and substantial real world use for the gene sequences.
Real-World Evidence: The Future of Data Generation and Usage
As data is captured through electronic health records, registries and unique device identifiers, the generation of evidence based on this data is expected to play a crucial role in informing orthopedic manufacturers’ decisions before and after regulatory approval. While regulators, payors, hospitals and manufacturers support this shift, they acknowledge that gaps remain in its optimal execution. Priority considerations include how to generate evidence to expedite regulatory market decisions, device indication expansion, postmarket studies, postmarket surveillance and reimbursement decisions. The National Evaluation System for health Technology Coordinating Center (NESTcc), an initiative of the Medical Device Innovation Consortium (MDIC), is leading the conversation with various stakeholders, including FDA and orthopedic device companies to support the sustainable generation of Real-World Evidence (RWE) using Real-World Data (RWD).
Photocatalysts lecture 2 bus model canvas
The document summarizes a research project led by Perena Gouma to commercialize nanocatalysts for water remediation. The nanocatalysts can efficiently decompose hydrocarbons and are intended to be used for oil decomposition and environmental cleanup. Potential customers include water remediation companies, coastal guards, shipping industries, and government environmental agencies. The project aims to validate the intellectual property, conduct pilot studies, establish partnerships for manufacturing and distribution, and generate revenue through direct sales, leasing, licensing, or partner channels. Market estimates suggest the total environmental nanotechnology market was $6.1 billion in 2010 and projections put the target remediation market over $8 billion.
Carbon cultures lecture 2 bus model canvas
The document discusses a company called C6 Systems that converts renewable forestry waste into a high-value soil amendment called biochar. C6 Systems operates using a mobile process that allows for the cost-effective production and removal of biochar from forests with low operating costs. The business model involves selling biochar to two main customer segments - landowners and biochar consumers, which includes agricultural, industrial, retail, and gardening users.
More Related Content
What's hot
Novoron I-Corps@NIH 121014
The document describes the evolution of a biotech startup's efforts to develop a new drug to treat spinal cord injury (SCI). Initially, the team was optimistic about validating the need and market potential. However, through customer interviews, they learned big pharma is not interested in early-stage SCI drugs due to previous failures. The team then developed a new 36-month plan to generate more rigorous preclinical data for FDA approval and attract partners. They also identified new financing options and pivoted to explore opportunities in multiple sclerosis based on stronger customer interest.
BioHybrid Graft I-Corps@NIH 121014
The document summarizes the progress of Team 21's bio-hybrid vascular graft project. It describes initial market research identifying unmet needs for small diameter vascular grafts. Through customer interviews, the team refined their target markets from coronary artery disease grafts to prioritizing peripheral artery disease grafts. Key lessons included identifying referring physicians as important influencers and pursuing CE mark in the EU followed by FDA approval. The team ended their canvas update at a higher level of investment readiness and prepared to apply for further STTR funding.
Magnamosis inc final presentation 12 10
The document outlines the progress of a team developing a magnetic compression device for surgical anastomoses. It includes:
1) The team has developed a device called Magnamosis to create magnetic compression anastomoses and has achieved milestones including animal trials and FDA approval for human trials.
2) Interviews with surgeons found reducing anastomotic leaks to be a key value proposition, as leaks increase costs and morbidity.
3) The team refined their business model based on feedback, deciding to focus early adoption in academic centers and use value-based pricing between $1,200-250 per device.
Abreos biosciences I-Corps@ NIH 121014
This document appears to be notes from a biotech startup working on drug authentication. It outlines the founders and advisors, progress made in validating customers and markets overseas, developing minimum viable products for different use cases, forming new partnerships, and progress towards an investment ready prototype. The startup has received several grants and is working to develop their prototype and secure further funding.
Liquilume NSF Final Presentation
LiquiLume Diagnostics develops molecular diagnostic devices that can detect individual molecules rapidly and inexpensively. Their initial focus is on nucleic acid testing (NAT) and protein biomarkers. They plan to first sell to research laboratories for research use only, then pursue FDA clearance to sell to clinical labs and hospitals. Their technology allows highly automated sample processing and analysis at low concentrations and low cost compared to standard methods.
Asclepix I-Corps@NIH 121014
The document summarizes the findings from 102 customer interviews conducted by an I-Corps team exploring a novel cancer therapy. Based on the interviews, the team pivoted from targeting head and neck cancer to glioblastoma, identified their customers as pharmaceutical licensing scouts and biotech executives rather than patients or doctors, and adjusted their preclinical strategy and partnerships to focus on demonstrating safety and efficacy while mitigating risks related to their nanotechnology approach.
Data Mining and Big Data Analytics in Pharma
The document proposes software solutions for drug research, including text mining, data warehousing, data mining, database development, and big data analytics. It discusses common challenges in drug research like the high costs and low success rates. It then describes various solutions like text mining patents and research to help identify new research opportunities and reduce duplication of efforts. It provides examples of how various pharmaceutical companies use data mining and warehousing techniques. Overall, the document pitches different IT solutions that can help pharmaceutical and life sciences companies address their research challenges and make their processes more efficient.
GJRS resume Jan 15
This document provides a summary of Greg J Spooner's career and qualifications. It includes his contact information, education history, and over 15 years of professional experience in developing lasers, optics, and medical devices. He has worked at several medical device companies and has 16 issued patents. His focus and expertise are in developing photonics-based medical devices, performing clinical applications research, product development, and regulatory submissions.
Gluco Sentient Final NSF I-Corps presentation
This document proposes a diagnostic platform that leverages existing personal glucose meters to provide direct readouts of target concentrations in patient samples. It suggests using this platform for therapeutic drug monitoring in clinical trials, medical diagnoses, and environmental detection. The initial target market was seen as diabetes patients who already own glucose meters and need HbA1c monitoring. However, immediate drug monitoring during clinical trials was identified as a better market that meets the value propositions of immediacy, low cost, multiple tests, and short development cycles. Partnerships with pharmaceutical companies are proposed, with GlucoSentient providing added value to meter manufacturers and the pharmaceutical companies being key customers and providing financial support.
BIO 2010 Partnering with Patients
The document discusses various ways that nonprofit organizations partner with patients and the medical research community to advance research and drug development. It provides examples of how organizations fund research, develop tools and resources, facilitate clinical trials, advocate for policy changes, and build communities to accelerate the development of new treatments. Specific organizations highlighted include the Alzheimer's Drug Discovery Foundation, Juvenile Diabetes Research Foundation, Multiple Myeloma Research Foundation, ALS Therapy Development Institute, and Genetic Alliance.
2012 DIA EMRs for clinical research
EMR functionality for clinical research has long been dreamed about, but how close to reality is it actually? This presentation lays out some basic facts about the viability (or lack thereof) of using EMRs for Phase 1-3 clinical trials.
D2M Final Presentation Submission for LinkedIn
This feasibility analysis examines developing a nucleic acid detection probe for fungal infections. It discusses the unmet need for rapid and accurate diagnosis of fungal sepsis in immunocompromised patients. Currently, diagnosis can take 2-4 days via blood culture and has low sensitivity. The proposed invention is a DNA-based probe that can detect fungal infections in 4-10 hours with higher sensitivity. The analysis covers the intellectual property landscape, potential licensees in biotech and diagnostics, licensing terms, and financial projections. It estimates the US market size as $900 million annually and projects revenues of $198 million within 5 years of licensing. However, the single patent expires in 2017. The recommendation is to donate the intellectual property to research
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...Medicines Discovery Catapult
The document discusses exploiting medicinal chemistry knowledge to accelerate drug discovery projects through in silico drug design techniques. It provides an agenda for a presentation covering problem statements around long development times, sources for design ideas like literature and patents, techniques for 2D and 3D molecular design including QSAR and docking models, and examples of applying these methods to specific drug targets. The presentation aims to explain how to analyze data rigorously and refine compound designs to find drug candidates faster.Webinar - State of the Discovery Nation 2019
The document is a report on the state of the UK drug discovery industry in 2019. It finds that most small and medium enterprises in the industry are service and supply companies, employing fewer than 20 people. The majority of drug development assets held by UK companies are focused on cancer, anti-infectives, and central nervous system disorders. Artificial intelligence and cell and gene therapies are seen as promising but in need of further validation and data. The report recommends that the government increase funding support and that the Medicines Discovery Catapult continue connecting companies, providing access to datasets and technologies, and helping to validate new models like complex cell models.
Maples PB Resume 010417
This document provides a biography for Phillip B. Maples, Ph.D., the Executive Director of Laurus Bio, LLC. It outlines his over 30 years of experience in cell and gene therapy development, including designing and building over 10 GMP manufacturing facilities. It also lists his roles and accomplishments at various biotech companies, including developing cell and gene therapies for cancer and inherited diseases and leading clinical trials.
Pharma data analytics
Presentation Alliance of European Life Sciences Law Firms
(Julian Hitchcock and Sofie van der Meulen) on legal aspects of big data in pharma. Topics: privacy, IP, medical devices and IVD.
J & J Solutions Executive Summary 1 Page
J & J Solutions has developed a closed system transfer device for safer handling of chemotherapy drugs. Their device eliminates risks of contamination, standardizes compounding to reduce errors, improves workflow efficiency, and reduces costs. They are seeking funding to complete product development including alpha and beta testing, obtain FDA approval, and launch the product to address a $1 billion market that is growing due to increasing cancer rates.
Team1 evening business-strategy_milestone1
23andMe is a privately-held personal genomics company based in Mountain View, CA that was founded in 2007. It provides genetic reports on over 100 diseases, conditions, and traits by analyzing customers' DNA samples. 23andMe aims to be the world's trusted source of personal genetic information while protecting customers' privacy and helping them understand their genetic data. It offers health, ancestry, and community services but lacks focus and customers are often confused by the breadth of information. The company needs to improve its marketing, user interface, and partnerships to help customers act on their genetic insights.
The Case Of Incyte Genomics
1) Incyte Genomics pursued an ambitious business model and patent strategy in the late 1990s and early 2000s that involved sequencing the human genome, patenting gene sequences, and selling subscriptions to genomic databases and licensing the patents.
2) A key part of the strategy was filing over 2,000 patent applications covering about 11,000 human gene sequences to generate licensing revenues, but this strategy faced challenges from the US Patent Office's utility requirement.
3) In 2004, Incyte abandoned its original business model and patent strategy after the US Patent Office rejected many of its patent applications for lack of demonstrating utility and specific and substantial real world use for the gene sequences.
Real-World Evidence: The Future of Data Generation and Usage
As data is captured through electronic health records, registries and unique device identifiers, the generation of evidence based on this data is expected to play a crucial role in informing orthopedic manufacturers’ decisions before and after regulatory approval. While regulators, payors, hospitals and manufacturers support this shift, they acknowledge that gaps remain in its optimal execution. Priority considerations include how to generate evidence to expedite regulatory market decisions, device indication expansion, postmarket studies, postmarket surveillance and reimbursement decisions. The National Evaluation System for health Technology Coordinating Center (NESTcc), an initiative of the Medical Device Innovation Consortium (MDIC), is leading the conversation with various stakeholders, including FDA and orthopedic device companies to support the sustainable generation of Real-World Evidence (RWE) using Real-World Data (RWD).
What's hot (20)
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
Real-World Evidence: The Future of Data Generation and Usage
Real-World Evidence: The Future of Data Generation and Usage
Viewers also liked
Photocatalysts lecture 2 bus model canvas
The document summarizes a research project led by Perena Gouma to commercialize nanocatalysts for water remediation. The nanocatalysts can efficiently decompose hydrocarbons and are intended to be used for oil decomposition and environmental cleanup. Potential customers include water remediation companies, coastal guards, shipping industries, and government environmental agencies. The project aims to validate the intellectual property, conduct pilot studies, establish partnerships for manufacturing and distribution, and generate revenue through direct sales, leasing, licensing, or partner channels. Market estimates suggest the total environmental nanotechnology market was $6.1 billion in 2010 and projections put the target remediation market over $8 billion.
Carbon cultures lecture 2 bus model canvas
The document discusses a company called C6 Systems that converts renewable forestry waste into a high-value soil amendment called biochar. C6 Systems operates using a mobile process that allows for the cost-effective production and removal of biochar from forests with low operating costs. The business model involves selling biochar to two main customer segments - landowners and biochar consumers, which includes agricultural, industrial, retail, and gardening users.
Graphene frontiers lecture 2 bus model canvas
Graphene Frontiers is working to commercialize a graphene production process that can produce higher quality graphene at lower cost than other methods. The company aims to scale production and license the technology to downstream fabrication companies in applications such as transparent conductors, chemical/bio sensors, and thermal management. An initial business model test will involve contacting potential customers in these segments to validate commercial interest and estimated demand.
Akra lighting lecture 2 bus model canvas
The document summarizes Arka Lighting's LED technology and business plan. It states that Arka's thermal solution has 50% greater heat dissipation capacity than current technologies, allowing for enhanced LED performance at reduced cost. It then discusses Arka's agenda to present its business model and pass/fail criteria, estimate market size, and plan to commercialize the technology. Key points include that over 27% of commercial energy is used for lighting and the global LED market is expected to reach $74 billion by 2020, representing Arka's initial addressable market of replacing the estimated 15 billion socket global installed base.
Lecture 2 value proposition
This document discusses value propositions and market types for new businesses. It begins with an agenda for discussing team bus model presentations, value propositions, and the product, service, or ecosystem being offered. It then covers defining and discovering the value proposition, including specifying the minimum viable product. Finally, it discusses the four types of markets - clone, existing, resegmented, and new - and how they determine customer adoption rates, sales and marketing strategies, and cash requirements. The key topics covered are defining the value proposition, minimum viable product, and determining the appropriate market type for a new business.
Lecture 1: Business Model & Customer Development
The document summarizes the key concepts from the Lean LaunchPad course, including business models, customer development, and pivoting. It explains that a business model describes all parts of a company necessary to make money. It then discusses customer development as a process involving customer discovery, validation, and creation to iteratively build a business model through pivoting based on customer feedback. The goal is to identify a repeatable and scalable business model in the search for a startup idea.
Sen severe final presentation
The document discusses the development of hydrogen sensors for monitoring hydrogen levels in chlor-alkali plants, which is led by a founding team with expertise in materials science, chemistry, and entrepreneurship. It outlines the value propositions and market needs for such sensors, including reliable and real-time detection capabilities to improve safety and efficiency in these hazardous industrial environments. Interviews with technology providers and industrial plant managers are being conducted to understand the economics and sensor requirements.
Ground flour pharma final presentation
The document discusses developing a new method for fluorinating compounds for positron emission tomography (PET) imaging using a single step. It notes the short half life of F-18 requires synthesis and injection within two hours. The solution presented is a single step fluorination process that could increase production 10-fold at the same cost and reduce side effects from unlabeled compounds. It then discusses engaging with various stakeholders in the radiopharmaceutical industry to develop the technology and business model.
Graphene frontiers final presentation
Graphene Frontiers is a nanotechnology company that has developed a proprietary atmospheric pressure chemical vapor deposition process for producing low-cost, high-quality graphene films at an industrial scale. They believe their scalable production process can accelerate the adoption of graphene and enable its integration into applications like flexible displays, solar cells, and touch screens. Through partnerships, further process development, and intellectual property creation, they aim to become the leading global producer of CVD graphene.
Photocatalysts final presentation
This document summarizes a company's photocatalyst nanotechnology product for water remediation.
- The product uses novel nanogrids to remove hydrocarbons from polluted water, such as from fracking operations, turning wastewater into drinkable water.
- The technology offers fast, efficient, and inexpensive decomposition of hydrocarbons with potential uses in environmental remediation and the multibillion dollar oil spill clean-up market.
Arka solutions final presentation
This document summarizes a business proposal for developing an enhanced cooling solution for LED lighting. Some key points:
- The global lighting industry is $100 billion, with LED lighting being a growing segment at $6 billion and over 40% CAGR.
- The team's initial concept was to develop LED replacement lamps with enhanced cooling to allow for higher output and quality. However, customer feedback indicated they were unwilling to adopt new technologies at current price points.
- The team then pivoted to focus on developing thermal modules and partnering with a heat exchanger manufacturer. This allows them to enter the market through established product lines rather than competing directly on lamps.
- Negotiations are ongoing with the
Fatal journeys (Team 621) Lessons Learned H4Dip Stanford 2016
agile, mission model, corporate innovation, customer development, h4d, h4dip, hacking for diplomacy, lean, lean launchpad, lean startup, stanford, steve blank, state department
Vitruvian week 10 presentation
This document summarizes research on preventing hernias. It includes:
1) A clinical trial of a tissue sealant product called MYOSEAL that showed it significantly reduced hernia rates in rats compared to saline or other treatments.
2) Interviews with surgeons, medical insurers, and a key opinion leader who said that with strong clinical data, most surgeons would adopt a hernia prevention method. However, some surgeons denied the extent of the hernia problem.
3) A business model canvas and timeline laying out the pre-clinical and clinical trial plans for MYOSEAL over 3 years with a total projected cost of $8.4 million. It identifies risks and options to de-
Knox final presentation
A team presented a remote monitoring device to help prevent severe asthma flare-ups in pediatric patients to potential investors. The investors were not interested in a solution that would only save $10 million and told the team to come back with a plan that could save $100 million. The investors were also not willing to provide data to the team. The document appears to be a report from the team outlining their presentation, feedback received, and business plans developed over 9 weeks to improve their solution.
BCN Biosciences I-corps@nih 121014
The document summarizes the findings from 101 interviews conducted by the BCN Biosciences Team over 10 weeks as part of the I-Corps program at NIH to validate the business model for a drug that increases the anti-cancer effect of radiation therapy in lung cancer. Through customer discovery interviews, the team identified fibrosis, specifically lung fibrosis and skin fibrosis, as larger market opportunities than their original focus on radiation mitigation. They evolved their strategy to focus on preventing radiation-induced lung fibrosis, lung fibrosis generally, and using the drug's anti-fibrotic properties for anti-aging applications.
Clinacuity I-Corps@NIH 121014
Team 09 presented their business model for an AI/NLP solution to extract clinical information like problems and allergies from unstructured clinical notes. They interviewed over 100 potential customers and refined their business model. Key elements include partnerships with EHR integration partners and EHR vendors, a sales force channel, and revenue from software licenses and support services. The solution aims to provide up to 20x faster patient chart review and 10x faster problem list entry.
Haro Pharmaceutical I-Corps@NIH 121014
This document summarizes meetings and interviews conducted by HaRo Pharmaceutical regarding development of a new drug to treat high-risk neuroblastoma. It discusses key activities like lead optimization, animal modeling, and clinical trials. Experts noted the importance of disease-relevant models and primary cell-based assays to generate convincing data. Clinical partners could support an IND application and initial trials. While the drug may have multiple indications, neuroblastoma requires more institutional support and approval from key opinion leaders. The document outlines HaRo's potential development path and identifies resources and partners needed at each stage.
Gammaglobulin I-Corps@NIH 121014
The document discusses developing a recombinant gammaglobulin product as an alternative to plasma-derived intravenous immunoglobulin (IVIG) treatments. It summarizes interviews with potential customers to understand their needs and determine the value proposition. Key stakeholders are identified as patients, healthcare providers, and regulators. Partners discussed include contract manufacturing organizations, clinical trial sites, and specialty pharmacies for distribution.
Viewers also liked (19)
Fatal journeys (Team 621) Lessons Learned H4Dip Stanford 2016
Fatal journeys (Team 621) Lessons Learned H4Dip Stanford 2016
Similar to Ground flour pharmaceuticals lecture 2 bus model canvas
Ground flour pharmaceuticals lecture 3 value prop
The document discusses developing new radiotracers for positron emission tomography (PET) imaging through efficient fluorination synthesis methods. It identifies initial target indications as pediatric neuroblastoma and Parkinson's disease. The business model would involve developing specific imaging agents, conducting clinical trials, and marketing the tracers and synthesis methods to radiopharmacies and imaging equipment companies.
Global radiopharmaceuticals market insight
“Global Radiopharmaceuticals Market Insight” Report Highlights
Global Radio Pharmaceuticals Market Overview by Region
Target Patient Base by Region
Radiopharmaceuticals Market Regulation for US, Europe & Canada
Radioisotopes Used in Radiopharmaceuticals
Radiopharmaceutical Clinical Pipeline Insight
Profile of 87 Radiopharmaceuticals Drugs in Clinical Phase
Global radiopharmaceuticals market insight
The global radiopharmaceuticals market was valued at $5.3 billion in 2013 and is expected to reach $10.6 billion by 2018, growing at a CAGR of 15%. Radiopharmaceuticals use radioactive isotopes to diagnose and treat diseases like cancer through PET/SPECT imaging and radiotherapy. Key drivers of growth include increasing adoption of PET/SPECT scanning and new targeted cancer treatments. However, high costs, short isotope half-lives, and regulatory hurdles need to be addressed to fully realize market opportunities.
2010StanfordE25 Michele dragoescu e25 project
This document discusses direct-to-consumer genetic testing, including its purposes and benefits, current examples, and privacy concerns. It also covers genetic sequencing techniques, pharmacogenomics, and predictions for the future of personalized medicine, including increasing market size and regulatory guidelines.
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meeting
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
Impact of Big Data & Artificial Intelligence in Drug Discovery & Development ...
Oral Presentation given at European Drug Discovery Innovation & Outsourcing Programme on 12th September 2023 in Barcelona. Overview around impact for AstraZeneca R&D from examples in the past 5+ years, including machine learning for safety assessment, augmenting digital pathology for image quantification & segmentation, and examples applying AI for right dose - identifying risk factors for CV patients and automated Population PK model prediction.
Organ Specific Proteomics
Organ Specific Proteomics as Presented by Paul Kearney, PhD; CSO, Integrated Diagnostics at the 2010 Personalized Health Care National Conference at Ohio State.
Sequencing Genomics: The New Big Data Driver
1. Genomic sequencing is driving big data as the cost of sequencing DNA falls faster than Moore's Law and the amount of data produced increases dramatically.
2. The Beijing Genome Institute is the world's largest genomic institute, using over 130 sequencing machines each producing 25 gigabases per day for a total of over 12 petabytes of data storage.
3. Interdisciplinary teams of computer scientists, data analysts, and geneticists are needed to analyze the massive amounts of genomic and metagenomic data being produced to gain insights into human health and disease.
BioSig Technologies Corporate Presentation - May 2015
BioSig has developed the PURE EP System, a next-generation electrophysiology (EP) information system, to improve cardiac signal recordings during ablation procedures. The document discusses the clinical need for better signal quality to optimize outcomes and efficiency. BioSig is validating the PURE EP System at leading cardiac centers and plans to submit an FDA 510(k) application in Q4 2015. The company has achieved key milestones on its development timeline and is supported by a proven management team and medical advisory board.
Fda phacilitate2010final
The document summarizes an FDA presentation on the regulation of cellular, tissue, and gene therapies. It provides an overview of the FDA organization relevant to these therapies. It discusses premarket review pathways, recent guidance documents, current activities around stem cells, gene therapy, and tissue safety, and international engagement efforts towards regulatory harmonization.
Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear...
Piramal Imaging will present new research on positron emission tomography (PET) imaging tracers at the Society of Nuclear Medicine and Molecular Imaging annual meeting, including data on the approved amyloid imaging agent florbetaben F18 and several investigational agents. Five abstracts provide new analyses on the clinical applications and impact of florbetaben amyloid-PET imaging. Additional abstracts present promising clinical trial data on the investigational tau tracer PI-2620 and agents for thrombus imaging (F-GP1) and cancer imaging (F-FSPG and Ga-RM2). Piramal Imaging aims to advance molecular imaging through developing novel PET tracers.
Personalized Medicine: Genetic Diagnostics Technologies
As medical understanding of the genotype/phenotype correlation of a disease becomes clearer, genetic testing can be expected to become a mainstay in the clinical setting. While the application of genetic testing to the clinical setting is very much in line with the larger medical goals of preventative and personalized medicine, there are many unanswered questions with regard to genetic testing.
Speakers: Dr. Mansoor Mohammed, Genomics Portraits Inc., Dr. Brian Underdown, Managing Director, MDS Capital, Dr. June Carroll, Sydney G. Frankfort Chair in Family Medicine Mt.Sinai Hospital, Dr. Peter N. Ray, Head, Molecular Genetics Department of Paediatric Laboratory Medicine. HSC Professor, Molecular and Medical Genetics, University of Toronto
Rodman and Renshaw Conference Presentation, November 2006
This document summarizes the presentation given by Advanced Cell Technology at the Rodman and Renshaw Conference in November 2006. It discusses ACT's leadership in regenerative medicine as the first to derive human embryonic stem cells through alternative methods. It outlines ACT's focus on retinal pigment epithelium, hemangioblast, and dermal product programs. It also provides updates on ACT's blastomere program and progress towards clinical trials for its RPE program. Key corporate milestones for 2006 and 2007 are identified.
mHealth Israel_Ryo Kosaka_AIST_National Institute of Advanced Industrial Scie...
Presentation by Ryo Kosaka, Senior Research Scientist, Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST). Includes an overview of priority strategies in Life Sciences and Biotech and description of the organization of the Life Sciences and Biotech department. Recent projects include a Portable System for High-Speed DNA Quantification, Application of a cell microarray chip for clinical diagnosis and single cell analysis, Safe and Secure Artificial Heart, New diagnosis for liver fibrosis utilizing glycans, AIST ventures from the department of Life Science & Biotech as well as International cooperation.
Cost on development of new drug
The document discusses the process and costs associated with drug development. It notes that the average cost to develop a new drug is $350 million to $5.5 billion and the process takes 6.5-7 years from discovery to approval. Key barriers to drug development include high financial costs, lengthy timelines for clinical trials, and regulatory hurdles. Approaches to reduce costs and timelines include greater use of electronic health records, simplifying clinical trial protocols, and utilizing decentralized clinical trial models.
Meg Ehm: Fueling a Genetics-Driven Drug Discovery Organization
Senior Director Meg Ehm, Human Genetics at GSK, at Genomics to Healthcare EU side event, 13 Sept 2019, THL, Helsinki
Avancées et nouveaux paradigmes en recherche clinique - Jean-Yves BLAY - Renc...
This document discusses new paradigms in clinical research. It notes that tumor biology is increasingly being understood at the molecular level, leading to a fragmentation of disease entities. Clinical trials now aim to target primary molecular alterations in tumors. Examples discussed include targeting KIT mutations in GIST and VEGF production as a secondary event. The document advocates understanding unexpected drug responses and evaluating pharmacodynamics. It concludes that understanding disease biology, molecular diagnostics, targeting primary alterations, and international collaboration are key to advances in clinical research.
PIPEs Conference Presentations, November 2006
This document discusses a presentation made at the PIPEs Conference in November 2006. It summarizes the company's focus on regenerative medicine using human embryonic stem cells, including their programs in retinal pigment epithelium cells, hemangioblasts, and dermal cells. It outlines the company's progress in building out GMP facilities, preclinical studies, and plans to file an IND for their RPE program by late 2007. Key milestones for 2006 and 2007 are also summarized.
Cancer genome repository_berkeley
1) Technology advances will soon enable sequencing a person's genome for under $1,000, exponentially increasing the number of sequenced genomes. However, this potential is limited without associating genomic data with clinical data and making it available for research.
2) A single genomic database containing inherited genomes and somatic mutations from cancer patients, along with other associated clinical and molecular data, is needed to avoid a piecemeal approach and maximize use.
3) Building such a "Million Cancer Genome Warehouse" poses technological challenges including dual clinical and research use, unified data storage and analysis, improving genomic analysis methods, streamlining data access, and ensuring privacy while enabling progress. Addressing these challenges could accelerate cancer treatment discovery.
MDC Connects: Evaluation of clinical preclinical pharmacodynamic endpoints us...
MDC Connects: Evaluation of clinical preclinical pharmacodynamic endpoints us...Medicines Discovery Catapult
Imaging can be used to evaluate pharmacodynamic endpoints in both preclinical and clinical studies. Preclinically, imaging such as PET can provide quantitative data on endpoints like tumor metabolism without invasive procedures. This can help reduce animal studies. Clinically, imaging biomarkers for conditions like osteoporosis, heart disease, and cancer provide anatomical and functional data on targets, proliferation, and hypoxia. Case studies demonstrate how imaging endpoints like tumor size and blood flow changes can support decision making in drug development from early research through approval. Imaging is positioned to continue advancing drug discovery by identifying new pharmacodynamic biomarkers.Similar to Ground flour pharmaceuticals lecture 2 bus model canvas (20)
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meeting
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meeting
Impact of Big Data & Artificial Intelligence in Drug Discovery & Development ...
Impact of Big Data & Artificial Intelligence in Drug Discovery & Development ...
BioSig Technologies Corporate Presentation - May 2015
BioSig Technologies Corporate Presentation - May 2015
Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear...
Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear...
Personalized Medicine: Genetic Diagnostics Technologies
Personalized Medicine: Genetic Diagnostics Technologies
Rodman and Renshaw Conference Presentation, November 2006
Rodman and Renshaw Conference Presentation, November 2006
mHealth Israel_Ryo Kosaka_AIST_National Institute of Advanced Industrial Scie...
mHealth Israel_Ryo Kosaka_AIST_National Institute of Advanced Industrial Scie...
Meg Ehm: Fueling a Genetics-Driven Drug Discovery Organization
Meg Ehm: Fueling a Genetics-Driven Drug Discovery Organization
Avancées et nouveaux paradigmes en recherche clinique - Jean-Yves BLAY - Renc...
Avancées et nouveaux paradigmes en recherche clinique - Jean-Yves BLAY - Renc...
MDC Connects: Evaluation of clinical preclinical pharmacodynamic endpoints us...
MDC Connects: Evaluation of clinical preclinical pharmacodynamic endpoints us...
More from Stanford University
Team Networks - 2022 Technology, Innovation & Great Power Competition
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, networks
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, LiOn Batteries
Team Quantum - 2022 Technology, Innovation & Great Power Competition
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, Quantum
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, Disinformation
Team Wargames - 2022 Technology, Innovation & Great Power Competition
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, Wargames
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, Acquistion
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Technology Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, climate
Altuna Engr245 2022 Lessons Learned
The document describes a team's efforts to commercialize a new protein quantification technology called PLA-Seq. After initially thinking the technology's value propositions of lower cost, faster throughput, and lower sample volume would appeal to pharmaceutical and personalized health companies, the team conducted customer interviews and learned accuracy was more important than cost to most customers. They also found their target markets should be preclinical biotech and academia rather than personalized health or CROs. The team incorporated their business and pivoted their marketing strategy and funding plans accordingly based on learnings outside of the building.
Invisa Engr245 2022 Lessons Learned
The document summarizes the development of Invisa Bio over 10 weeks as they pivoted between different medical applications and solutions for their self-assembling medical device technology. They initially focused on manufacturing and delivery but shifted to leveraging drug delivery mechanisms. They considered applications in cardiology, neurology, and orthopedics before focusing on brain aneurysms based on feedback from physicians. The company incorporated, raised funding, and began shadowing doctors to further develop their technology to address unmet needs in difficult to reach areas.
ānanda Engr245 2022 Lessons Learned
(1) The document describes the journey of a team developing a saffron supplement product to address mental health issues like anxiety and depression.
(2) It started with the goal of targeting adults aged 18-40, but through customer interviews and testing, they learned that teenagers were more interested in an anti-anxiety gummy product.
(3) Key lessons included the challenges of building the right team, navigating advice, knowing when enough customer feedback has been received, and setting individual and project milestones. The team is now continuing work over the summer to further develop the product.
Gordian Knot Center Roundtable w/Depty SecDef
Kathleen Hicks - Deputy secretary of defense- visit to the Stanford Gordian Knot Center for National Security Innovation
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, Army venture capital
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve Blank, Army Venture capital
Team Catena - 2021 Technology, Innovation & Great Power Competition
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, economic coercion,
Team Apollo - 2021 Technology, Innovation & Great Power Competition
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, space force
Team Drone - 2021 Technology, Innovation & Great Power Competition
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, c3i, command and control
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, semiconductors
Team Aurora - 2021 Technology, Innovation & Great Power Competition
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, Army venture capital
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, venture capital
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
Technology, Innovation and Great Power Competition,TIGPC, Gordian knot Center, DIME-FIL, department of defense, dod, hacking for defense, intlpol 340, joe felter, ms&e296, raj shah, stanford, Steve blank, AI, ML, AI/ML, china, unmanned, autonomy, Michael Sulmeyer, cybercom,USCYBERCOM
More from Stanford University (20)
Team Networks - 2022 Technology, Innovation & Great Power Competition
Team Networks - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
Team Quantum - 2022 Technology, Innovation & Great Power Competition
Team Quantum - 2022 Technology, Innovation & Great Power Competition
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
Team Wargames - 2022 Technology, Innovation & Great Power Competition
Team Wargames - 2022 Technology, Innovation & Great Power Competition
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power Competition
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
Recently uploaded
Leveraging Generative AI to Drive Nonprofit Innovation
In this webinar, participants learned how to utilize Generative AI to streamline operations and elevate member engagement. Amazon Web Service experts provided a customer specific use cases and dived into low/no-code tools that are quick and easy to deploy through Amazon Web Service (AWS.)
How to Create a More Engaging and Human Online Learning Experience
How to Create a More Engaging and Human Online Learning Experience Wahiba Chair Training & Consulting
Wahiba Chair's Talk at the 2024 Learning Ideas Conference. LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
clinical examination of hip joint (1).pdf
described clinical examination all orthopeadic conditions .
How to Build a Module in Odoo 17 Using the Scaffold Method
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
PCOS corelations and management through Ayurveda.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
How to Make a Field Mandatory in Odoo 17
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar KanvariaISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
Denis is a dynamic and results-driven Chief Information Officer (CIO) with a distinguished career spanning information systems analysis and technical project management. With a proven track record of spearheading the design and delivery of cutting-edge Information Management solutions, he has consistently elevated business operations, streamlined reporting functions, and maximized process efficiency.
Certified as an ISO/IEC 27001: Information Security Management Systems (ISMS) Lead Implementer, Data Protection Officer, and Cyber Risks Analyst, Denis brings a heightened focus on data security, privacy, and cyber resilience to every endeavor.
His expertise extends across a diverse spectrum of reporting, database, and web development applications, underpinned by an exceptional grasp of data storage and virtualization technologies. His proficiency in application testing, database administration, and data cleansing ensures seamless execution of complex projects.
What sets Denis apart is his comprehensive understanding of Business and Systems Analysis technologies, honed through involvement in all phases of the Software Development Lifecycle (SDLC). From meticulous requirements gathering to precise analysis, innovative design, rigorous development, thorough testing, and successful implementation, he has consistently delivered exceptional results.
Throughout his career, he has taken on multifaceted roles, from leading technical project management teams to owning solutions that drive operational excellence. His conscientious and proactive approach is unwavering, whether he is working independently or collaboratively within a team. His ability to connect with colleagues on a personal level underscores his commitment to fostering a harmonious and productive workplace environment.
Date: May 29, 2024
Tags: Information Security, ISO/IEC 27001, ISO/IEC 42001, Artificial Intelligence, GDPR
-------------------------------------------------------------------------------
Find out more about ISO training and certification services
Training: ISO/IEC 27001 Information Security Management System - EN | PECB
ISO/IEC 42001 Artificial Intelligence Management System - EN | PECB
General Data Protection Regulation (GDPR) - Training Courses - EN | PECB
Webinars: https://pecb.com/webinars
Article: https://pecb.com/article
-------------------------------------------------------------------------------
For more information about PECB:
Website: https://pecb.com/
LinkedIn: https://www.linkedin.com/company/pecb/
Facebook: https://www.facebook.com/PECBInternational/
Slideshare: http://www.slideshare.net/PECBCERTIFICATION
Wound healing PPT
This document provides an overview of wound healing, its functions, stages, mechanisms, factors affecting it, and complications.
A wound is a break in the integrity of the skin or tissues, which may be associated with disruption of the structure and function.
Healing is the body’s response to injury in an attempt to restore normal structure and functions.
Healing can occur in two ways: Regeneration and Repair
There are 4 phases of wound healing: hemostasis, inflammation, proliferation, and remodeling. This document also describes the mechanism of wound healing. Factors that affect healing include infection, uncontrolled diabetes, poor nutrition, age, anemia, the presence of foreign bodies, etc.
Complications of wound healing like infection, hyperpigmentation of scar, contractures, and keloid formation.
BBR 2024 Summer Sessions Interview Training
Qualitative research interview training by Professor Katrina Pritchard and Dr Helen Williams
How to Fix the Import Error in the Odoo 17
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
Physical pharmaceutics notes for B.pharm students
The Diamonds of 2023-2024 in the IGRA collection
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...National Information Standards Organization (NISO)
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.Recently uploaded (20)
Leveraging Generative AI to Drive Nonprofit Innovation
Leveraging Generative AI to Drive Nonprofit Innovation
How to Create a More Engaging and Human Online Learning Experience
How to Create a More Engaging and Human Online Learning Experience
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
How to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold Method
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Ground flour pharmaceuticals lecture 2 bus model canvas
- 1. I-Corps 10/11/2011 Advanced Chemistry for Pharmaceutical Progress Team: Kiel Neumann (EL) Stephen DiMagno (PI) Allan Green (Mentor)
- 3. General methodology for adding fluorine to lead compounds of interest The Business Model Canvas Accessibility (RCY) Purity Speed PET/SPECT Multiplatform Sensitivity (nca) Specific compounds IP PoP data Regulatory plan Understanding of the regulatory process Contract cGMP precursor manufacture Salary, Rents Clinical trials SOPs for precursors and drugs Recruit clinical sites In vivo animal studies Develop regulatory plan for pre IND meeting ID cGMP CRO Fund-raising cGMP manufacturer Radiopharmacies Nuclear Medicine and Radiology departments Technical Assistance (Image Atlas) FDA regulatory support Radiopharmacies Equipment producers Prescribing physicians Radiologist who perform studies Sales of intermediates Technology license Product license (royalty) Direct sales of precursor R&D and clinical studies presented in journals and meetings Drug developers Pharmaceutical development companies IP PoP data Radiologists Technical assistance
- 4. I-Corps 10/11/11 Approximately 2.2 million procedures in the US. Drug costs range from $700 (on-patent) to ~$150 (generic FDG) US sales of radiopharmaceuticals for PET and SPECT $1.2 billion US sales expected to grow to $6 billion by 2018 Global numbers approximately 2x Source: Bio-Tech Systems Report #330; data for 2010.
- 5. I-Corps 10/11/11 2500 installed PET scanners PET radiopharmacies cover the entire US market Radiopharmacies have an interest in proprietary agents as a basis of competition in their market.
- 6. I-Corps 10/11/11 Neuroblastoma Prevalence: about 6000 US cases about 1000 new cases per year Subjects receive 3-6 images/year to follow response to therapeutic protocols World market at U.S. x 2 gives potential of 40,000-70,000 scans/year Drug costs $500/per gives ~$20 - $35 M Parkinson’s Disease DatSCAN sales in Europe ~$100 M The world's highest recorded prevalence of Parkinson's Disease of any region is in Nebraska, with 329.3 people per 100,000 population US – 600,000 patients 1 scan per year @ $500 = $300 M